Tin tức & Cập nhật
Xem bài viết Dược
Xem
Osmotic-release oral system methylphenidate of little help in ADHD
Treatment with osmotic-release oral system methylphenidate falls short of reducing symptoms of attention-deficit hyperactivity disorder (ADHD) in young adult prisoners, as shown in a study.
Osmotic-release oral system methylphenidate of little help in ADHD
29 Dec 2022
TACE + apatinib: A potential new strategy for intermediate/advanced HCC?
In patients with intermediate or advanced hepatocellular carcinoma (HCC), combining transarterial chemoembolization (TACE) with apatinib led to improvement in progression-free survival (PFS), according to a recent study from China.
TACE + apatinib: A potential new strategy for intermediate/advanced HCC?
28 Dec 2022
Updated monarchE results show improved treatment effects of abemaciclib for breast cancer
In the preplanned overall survival (OS) interim analysis of the monarchE study, the combination of abemaciclib and endocrine therapy (ET) continued to provide benefit for individuals with HR+, HER2–, node-positive, high-risk early breast cancer even after completion of therapy.
Updated monarchE results show improved treatment effects of abemaciclib for breast cancer
28 Dec 2022
Sovateltide: A new option to improve neuro outcomes after cerebral ischaemic stroke?
The endothelin-B receptor agonist sovateltide appears to improve neurological outcomes in patients with acute cerebral ischaemic stroke (ACIS), according to a phase III trial presented at WSC 2022.
Sovateltide: A new option to improve neuro outcomes after cerebral ischaemic stroke?
26 Dec 2022
Prasugrel tops ticagrelor for reducing risk of ischaemic events in ACS patients with prior MI
Prasugrel appears to better protect against the risk of ischaemic events in patients with acute coronary syndrome (ACS) and prior myocardial infarction (MI) as compared with ticagrelor, without a trade-off in bleeding, a study has found.